Lumakras FDA Approval History
Last updated by Judith Stewart, BPharm on June 2, 2021.
FDA Approved: Yes (First approved May 28, 2021)
Brand name: Lumakras
Generic name: sotorasib
Dosage form: Tablets
Company: Amgen Inc.
Treatment for: Non Small Cell Lung Cancer
Lumakras (sotorasib) is a KRASG12C inhibitor for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non- small cell lung cancer (NSCLC), following at least one prior systemic therapy.
- This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Development timeline for Lumakras
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.